newsfilter
← Latest News
Business Wire·

Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory

  • Quanterix Corporation announced an exclusive distribution agreement with Brooklyn-based Sherman Abrams Laboratory on November 16, 2026.
  • The partnership enables expanded access to LucentAD® Complete blood tests for patients in New Jersey, New York, & Connecticut.
  • LucentAD® Complete utilizes the SIMOA® platform to screen for multiple biomarkers associated with Alzheimer's disease.
  • The agreement targets individuals showing signs of or at risk for Alzheimer's who have not yet received a formal diagnosis.
  • Sherman Abrams Laboratory will offer the testing to its network of referring physicians across the Metro NY/NJ region.
  • Quanterix CEO Everett Cunningham stated the partnership aims to close access gaps & improve patient outcomes.
  • Sherman Abrams Executive Vice President Sal Prifitera noted the collaboration advances diagnostic capabilities for informed clinical decisions.
  • Quanterix acquired Akoya Biosciences in 2025, adding spatial biology imaging to its portfolio & bringing the combined company's total to 1,439 installed instruments.
  • Sherman Abrams Labs, established in 1964, serves various healthcare facilities including hospitals, nursing homes, & home-bound patients.